Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Earlier patient access to beneficial therapeutics that addresses unmet need is one of the main requirements of innovation in global healthcare systems already burdened by unsustainable budgets. "Adaptive pathways" encompass earlier cross-stakeholder engagement, regulatory tools, and iterative evidence generation through the life cycle of the medicinal product. A key enabler of earlier patient access is through more flexible and adaptive payer approaches to pricing and reimbursement that reflect the emerging evidence generated.

Original publication

DOI

10.1002/cpt.508

Type

Journal

Clinical pharmacology and therapeutics

Publication Date

12/2016

Volume

100

Pages

730 - 742

Addresses

Centre for Advancement for Sustainable Medical Innovation (CASMI), University of Oxford, Oxford, United Kingdom.

Keywords

Humans, Time Factors, European Union, Diffusion of Innovation, Costs and Cost Analysis, Budgets, Reimbursement Mechanisms, Health Services Needs and Demand, Delivery of Health Care, Health Services Accessibility, United States